Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be ...

Texas reports no new measles cases for the first time since February, maintaining 742 total cases. Meanwhile, Novo Nordisk's Ozempic is linked to rare serious eye disorders, possibly causing vision ...

Novo Nordisk Thailand has signed an MoU with HSRI – and the Health Systems Research Institute  – to strengthen Thailand’s clinical research infrastructure and foster healthcare innovation. The ...

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...